Negmatova Gulzoda Shukhratovna , Togaeva Gulnora Siddiqovna , Davranova Aziza Davranovna, Azimbegova Sitora Nodirovna
The medical and social significance of type 1 diabetes mellitus (DM) throughout the world is due to early disability and high mortality in patients due to the development of complications, including those from the cardiovascular system. The increase in the life expectancy of patients with diabetes has highlighted the problem of late complications of the disease, the number of which increases with the progression of the disease. The leading cause of death in diabetic patients is cardiovascular accidents. At the same time, it was found that patients with diabetes under the age of 30 years quite often develop coronary heart disease. In addition, the progression of diabetes leads to the development of cardiomyopathy (myocardial dystrophy), myocardiosclerosis, heart failure, life-threatening cardiac arrhythmias,
and sudden cardiac death. Interest in the study of diabetic cardiomyopathy (PrEP) is due to a true increase in the frequency of its occurrence in common pathology of social significance and the emergence of new instrumental research methods (Doppler echocardiography, 24-hour monitoring of heart rate and blood pressure), which significantly improved diagnostic
capabilities.
One of the drugs used in cardiology for metabolic purposes is Nikavit Cardio, the mechanism of action of which is associated with the direct inhibition of fatty acid oxidation. The latter is accompanied by a significant increase in the intensity of oxidative phosphorylation and a decrease in acidosis in the cardiomyocyte. A number of clinical studies have shown the high efficiency of Nikavit Cardio, the effectiveness and safety of the use of Nikavit Cardio, due to its cytoprotective mechanism of action, which makes it possible to prescribe it to patients with diabetes mellitus.
